Stocks
Mutual Funds
ETFs
Pro Tools
Terminal
WealthView
Pricing
Learn More
stocks
MARKSANS
MARKSANS

Marksans Pharma Ltd.

NSE: MARKSANS
BSE: 524404
Sector: Healthcare
Industry: Pharmaceuticals
335.90+0.8 (+0.25%)
8 Sep, 12:00 AM

Stock Scores

Quality Score

92.2 / 100

Value Score

40.9 / 100

Price Momentum Score

97.1 / 100

QVM Score

96.1 / 100

Key Metrics

Market Cap
15221.80
P/E (TTM)
29.33
P/B
5.04
P/S (TTM)
4.80
EV/EBITDA
20.42
CAPE (5Y)
44.89
ROE (TTM)
15.22
ROCE (TTM)
16.26
ROA (TTM)
11.77
Avg 3Y ROE
16.16
Earnings 3Y CAGR
20.94
Sales 3Y CAGR
18.25
Sales 5Y CAGR
17.87
Debt/Equity
0.11
Consensus TP
294.00
Strong Buy %
-
Promoter Holding
43.87
Pledged %
0.00

Share Price

Track Marksans Pharma Ltd.'s current share price, historical price chart, 52-week high/low, and performance across different time periods.

335.900.8 (0.25%)
98.17% in past 1 year
1 Week returns: 4.19 %
Low
318.8
High
350.0
1 Month returns: 22.66 %
Low
268.3
High
350.0
1 Year returns: 98.17 %
Low
155.0
High
350.0
3 Year CAGR: 46.99 %
Low
97.4
High
358.7
5 Year CAGR: 36.26 %
Low
38.6
High
358.7
Note: Prices may be delayed by a few minutes. For historical calculations, prices are adjusted for splits, bonus and rights issue. Percentage change shown is absolute irrespective of the period.

Stock Analysis

Fundamental analysis overview of Marksans Pharma Ltd. covering key investment insights, growth drivers, risk factors, and potential red flags.

Views
Red Flags
Positive
Strong price momentum

Price Momentum score of 97.1 indicates that the stock has strong price momentum. Research has shown that stocks with higher momentum continue to outperform in the near term

What is Price Momentum score?

97.1 / 100

Analysts have been raising forward EPS estimates

Analyst EPS estimate (consensus) for forward EPS has increased by 4.49% in the last 3 months, indicating earnings momentum

What is Earnings upgrade (3M)?

10.6Apr 2611.37May 2611.53Jun 2611.69Jul 2612.39Aug 2612.43Sep 26
High and stable operating margin

The company reported strong operating margin of 17.1% for 12-month ended 30 Jun 2026 and operating margin improved marginally by 148 bps from 1 year ago

What is Operating profit margin?

Moderate revenue growth and above median growth of industry

The company delivered moderate revenue growth of 19.59% for 12-month ended 30 Jun 2026 and the growth was 9.0 percentage points higher than median growth of industry

What is Sales growth (1Y)?

Median: 10.59
Value 19.59
-99.6111701.8
Strong EPS growth and above median growth of industry

The company delivered strong EPS growth of 47.59% for 12-month ended 30 Jun 2026 and the growth was 40.39 percentage points higher than median growth of industry

What is EPS growth (1Y)?

Low Debt to Equity, not much change from last year

The company has low Debt to Equity of 0.11 as on 30 Jun 2026 and Debt to Equity decreased marginally by 0.02 in the last 1 year

What is Debt to Equity?

Consistently pays dividend

The company has not missed dividend payments once in the last 10 financial years

What is Dividend streak?

Company is net cash

The company is net cash i.e., cash and cash equivalents exceed total debt indicating a healthy balance sheet

What is Net Debt ?

Negative
Expensive and at same valuation levels as industry median P/E

PE TTM of 29.33 indicates that the stock is expensive on a standalone basis. Discount to industry median P/E is modest at -7.71%

What is P/E Ratio?

Median: 31.78
Value 29.33
-0.96721.13
Low dividend yield

The company has a low dividend yield of 0.27%

What is Dividend yield?

Neutral
High ROE but declining trend

The company reported strong ROE of 15.22% for 12-month ended 30 Jun 2026 but ROE declined by -158 bps from 1 year ago

What is ROE (FY)?

Company's earnings are of moderate quality

Earnings quality score of 66.8 indicates that the company's earnings are of moderate quality. Earnings quality is measured using combination of earnings persistence, probability of manipulation and earnings to cash conversion

What is Earnings quality score?

66.8 / 100

No red flags found!
No significant red flags found in the stock.

Financial Snapshot

See detailed analysis

Multi-year trends for Marksans Pharma Ltd. covering revenue, net profit, ROE, and EBITDA for a quick view of financial health over time.

Net Revenue FY
01k2k3k1.9 K CrMar 20232.2 K CrMar 20242.6 K CrMar 20253.0 K CrMar 2026
Profit After Tax FY
00k0k1k266.3 CrMar 2023423.5 CrMar 2024380.6 CrMar 2025417.9 CrMar 2026
ROE FY
0%10%20%30%18.1%Mar 202322.2%Mar 202416.8%Mar 202515.2%Mar 2026
EBITDA FY
00k0k1k1k350.4 CrMar 2023735.7 CrMar 2024528.6 CrMar 2025603.4 CrMar 2026

Marksans Pharma Ltd. Shareholding Pattern

Quarterly breakdown of Marksans Pharma Ltd. ownership including promoter, FII, DII, mutual fund, and public holdings as disclosed to NSE/BSE.

Mar 2020Jun 2020Sep 2020Dec 2020Mar 2021Jun 2021Sep 2021Dec 2021Mar 2022Jun 2022Sep 2022Dec 2022Mar 2023Jun 2023Sep 2023Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026Jun 2026
Total Promoter
48.25
48.25
48.25
48.25
48.25
48.25
48.25
48.25
48.25
48.25
48.60
49.00
43.85
43.85
43.85
43.85
43.85
43.87
43.87
43.87
43.87
43.87
43.87
43.87
43.87
43.87
Indian Promoter
48.25
48.25
48.25
48.25
48.25
48.25
48.25
48.25
48.25
48.25
48.60
49.00
43.85
43.85
43.85
43.85
43.85
43.87
43.87
43.87
43.87
43.87
43.87
43.87
43.87
43.87
Foreign Promoter
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
Institutions
3.43
3.95
4.99
5.35
4.68
3.70
3.17
3.00
3.93
4.98
5.01
5.20
16.58
18.56
19.09
20.32
20.74
22.34
25.41
26.26
26.76
25.38
22.20
14.03
23.33
23.66
Mutual Funds / UTI
-
-
-
0.01
0.09
0.34
0.34
0.34
0.46
0.95
0.95
0.96
0.86
2.79
3.15
3.82
4.23
2.82
3.02
3.15
3.37
3.55
3.92
4.41
4.66
4.36
FI/Bank/Insurance
0.64
0.43
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Govt
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
FII
2.54
3.28
4.69
5.05
4.34
3.14
2.64
2.59
3.46
4.04
4.06
4.23
15.11
14.90
15.07
15.55
15.57
18.59
21.31
21.95
22.19
19.89
16.92
8.13
16.76
17.47
Other Institutions
0.30
0.44
1.25
0.29
0.24
0.81
0.19
0.07
0.00
0.00
0.00
0.00
0.60
0.86
0.87
0.94
0.94
0.93
1.08
1.15
1.19
1.95
1.36
1.50
1.91
1.83
Non-Institution
48.32
47.80
46.76
46.40
47.07
48.05
48.58
48.75
47.82
46.77
46.38
45.80
39.58
37.59
37.06
35.83
35.40
33.78
30.71
29.87
29.37
30.75
33.93
42.09
32.79
32.47
Bodies Corporate
1.94
1.97
1.71
1.81
1.77
2.49
2.41
2.65
2.68
2.61
2.54
2.44
2.13
2.30
2.06
2.07
1.52
1.50
1.42
1.25
1.30
1.67
1.83
1.92
1.90
1.79
Others (incl. Retail)
No. of shareholders
46.38
1,22,695
45.83
1,23,694
45.05
1,25,500
44.59
1,29,590
45.30
1,34,766
45.56
1,88,306
46.17
2,00,872
46.10
2,14,432
45.14
2,19,541
44.16
2,20,811
43.84
2,17,212
43.36
2,12,580
37.45
1,97,822
35.29
1,87,848
35.00
2,07,283
33.76
2,36,712
33.88
2,54,015
32.28
2,34,839
29.29
2,47,944
28.62
2,58,854
28.07
2,56,400
29.08
2,55,069
32.10
2,64,527
40.17
2,53,958
30.89
2,45,093
30.68
2,45,433

Holdings and Presence

Indices and prominent investors with a stake in this stock.

Index Presence
#IndexWeightRank
1Nifty Microcap 2500.61%40 / 250
2Nifty Total Market0.03%439 / 749

Bulk, Block and Insider Trades

Recent bulk deals, block deals, and insider trading activity in Marksans Pharma Ltd. shares as reported to NSE and BSE.

NameMonthTransactionHolding % pre transactionAverage priceQty.Transaction value
Sandra Saldanha
Promoter
June-2024
Market Purchase (Acquisition)
6th Jun 2024
0.06 %₹ 141.4863.28 k₹ 89.52 lac
Sandra Saldanha
Promoter
June-2024
Market Purchase (Acquisition)
4th Jun 2024
0.05 %₹ 146.0147.00 k₹ 68.62 lac
Arvind Singh
Employee
August-2023
Market Purchase (Acquisition)
22nd Aug 2023
0.00 %₹ 115.753.00 k₹ 3.47 lac
Arvind Singh
Employee
August-2023
Market Sale (Disposal)
22nd Aug 2023
0.00 %₹ 114.903.00 k₹ 3.45 lac
Arvind Singh
Employee
August-2023
Market Sale (Disposal)
22nd Aug 2023
0.00 %₹ 163.922.00 k₹ 3.28 lac
Arvind Singh
Employee
August-2023
Market Sale (Disposal)
22nd Aug 2023
0.00 %₹ 117.066.50 k₹ 7.61 lac
Sandra Saldanha
Promoter
March-2023
Market Purchase (Acquisition)
16th Mar 2023
0.02 %₹ 66.691.45 lac₹ 96.70 lac
Mark Saldanha
Promoter
March-2023
Conversion of security (Acquisition)
2nd Mar 2023
43.58 %₹ 74.0010.00 lac₹ 7.40 cr
Sandra Saldanha
Promoter
March-2023
Market Purchase (Acquisition)
1st Mar 2023
0.00 %₹ 67.4675.00 k₹ 50.60 lac

Corporate Actions

History of Marksans Pharma Ltd. dividends, bonus issues, stock splits, rights issues, and other corporate events.

  1. Dividend₹ 0.90/share
    Record date: 20th Aug 2026Ex-date: 20th Aug 2026
    Announced on: 26th May 2026
  2. Dividend₹ 0.80/share
    Record date: 1st Aug 2025Ex-date: 1st Aug 2025
    Announced on: 19th May 2025
  3. Dividend₹ 0.60/share
    Record date: 17th Sep 2024Ex-date: 17th Sep 2024
    Announced on: 30th May 2024
  4. Dividend₹ 0.50/share
    Record date: 7th Jun 2023Ex-date: 7th Jun 2023
    Announced on: 24th May 2023
  5. Dividend₹ 0.25/share
    Record date: 22nd Aug 2022Ex-date: 19th Aug 2022
    Announced on: 31st May 2022

Company Profile

Overview of Marksans Pharma Ltd. covering business description, industry classification, key management, financial ratios, and listed exchange details.

Marksans Pharma Limited is engaged in research, manufacture, marketing and sales of pharmaceutical formulations. It operates two manufacturing facilities in Goa and maintains two research and development centers; one located in Goa and the other in Navi Mumbai. Its focus areas lie in the over the co...
Key personnel
Mr. Jitendra Sharma
Group Chief Financial Officer
Mr. Harshavardhan Panigrahi
Company Secretary, Compliance Officer
Mr. Sathish Kumar
Managing Director - UK Operations
Mr. David Mohammed
Managing Director - Australia Operations
Mr. Anjani Kumar
Chief Operating Officer - US Operations
Mr. Mark B. SaldanhaD
Executive Chairman of the Board, Managing Director
Mr. Varddhman Vikramaditya JainD
Whole Time Director
Mrs. Sandra SaldanhaD
Whole Time Director
View all
Incorporated on
16 Apr 1992
Last Annual
31 Mar 2026
Last Interim
30 Jun 2026
No. of Employees
1,685
IPO date
03 Apr 2002
Free Float
21,52,90,856
Phone no.
+912240012000
Address
11th Floor Grandeur,, Off Veera Desai Road, Opp Gundecha Symphony,Andheri (W), MUMBAI, 400053, India

Frequently Asked Questions

What is the current share price of Marksans Pharma Ltd.?
The current share price of Marksans Pharma Ltd. is ₹ 335.90 as of 8 Sep 2026.
What is the market capitalisation of Marksans Pharma Ltd.?
The market capitalisation of Marksans Pharma Ltd. stands at ₹ 15,221.80 Cr.
What is the PE ratio of Marksans Pharma Ltd.?
The Price-to-Earnings (PE) ratio of Marksans Pharma Ltd. is 29.33 as of the latest trailing twelve months data.
What is the ROE and ROCE of Marksans Pharma Ltd.?
Marksans Pharma Ltd. has a Return on Equity (ROE) of 15.22% and a Return on Capital Employed (ROCE) of 16.26% as per the latest financial reports.
What is the 52-week high and low of Marksans Pharma Ltd.?
The 52-week high of Marksans Pharma Ltd. is - and the 52-week low is -.
What is the dividend yield of Marksans Pharma Ltd.?
The dividend yield of Marksans Pharma Ltd. is 0.27% based on the current market price.
What is the FII and DII holding in Marksans Pharma Ltd.?
Foreign Institutional Investors (FII) hold 17.47%, Domestic Institutional Investors (DII) hold 4.36% and retail/public investors hold 30.68% of Marksans Pharma Ltd. shares.
What sector does Marksans Pharma Ltd. belong to?
Marksans Pharma Ltd. operates in the Healthcare sector.
What is the beta of Marksans Pharma Ltd.?
The beta of Marksans Pharma Ltd. is 0.98, indicating its price volatility relative to the broader market. Over the past 1 year, Marksans Pharma Ltd. has delivered an absolute return of 96.43%.
What is the RSI of Marksans Pharma Ltd.?
The 14-day Relative Strength Index (RSI) of Marksans Pharma Ltd. is 65.25, placing it approaching overbought territory. An RSI above 70 is considered overbought and below 30 is considered oversold.